![STAT+: ‘This is an industry that everyone [bleeping] hates’](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-1024x576.jpg?#)
.jpg)
Sanofi taps Nurix for pipeline nourishment once again, picking up autoimmune degrader for $15M
Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable transcription factor.
Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 million for exclusive rights to a degrader of a once-undruggable transcription factor.
